Regadenoson Stress Testing: A Comprehensive Review With a Focused Update

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2021 Mar 3

PMID 33654619

Citations 6

Authors

Karim O Elkholy

Omar Hegazy

Adeniyi Okunade

Suat Aktas

Temitope Ajibawo

Affiliations

Soon will be listed here.

Abstract

Regadenoson is a pharmacological stress agent that has been widely used since its approval by the Food and Drug Administration (FDA) in 2008. For many years, dipyridamole and adenosine, which are non-selective adenosine receptor agonists, were more popular. However, these agents are less preferred now due to their undesirable adverse effects as compared to regadenoson. In the ADVANCE (ADenoscan Versus regAdenosoN Comparative Evaluation) phase 3 clinical trial, regadenoson demonstrated non-inferiority to adenosine for detecting reversible myocardial ischemia. This review summarizes the clinical utilities of regadenoson as the most widely used pharmacological stress agent. Moreover, the use of regadenoson has been documented in specific patient populations. Although regadenoson has established safety and efficacy in most patients with chronic diseases, there are equivocal results in the literature for other chronic diseases. It is warranted to highlight that the use of regadenoson has not been studied in patients of low socioeconomic class; it is a condition that carries a significant burden on the cardiovascular system.

Citing Articles

Know Your ABCs: Discovery, Differentiation, and Targeting of T-Bet+ B Cells.

Winslow G, Levack R Immunol Rev. 2025; 330(1):e13440.

PMID: 39844597 PMC: 11754996. DOI: 10.1111/imr.13440.

State of the art of CT myocardial perfusion.

Muscogiuri G, Palumbo P, Kitagawa K, Nakamura S, Senatieri A, De Cecco C Radiol Med. 2024; 130(3):438-452.

PMID: 39704963 DOI: 10.1007/s11547-024-01942-4.

Diagnostic Modalities in Heart Failure: A Narrative Review.

Tanisha , Amudha C, Raake M, Samuel D, Aggarwal S, Bashir Z Cureus. 2024; 16(8):e67432.

PMID: 39314559 PMC: 11417415. DOI: 10.7759/cureus.67432.

Timing of Regadenoson-induced Peak Hyperemia and the Effects on Coronary Flow Reserve.

Kattapuram N, Shadman S, Morgan E, Benton C, Awojoodu S, Kim D medRxiv. 2024; .

PMID: 38410488 PMC: 10896412. DOI: 10.1101/2024.01.15.23300449.

Splenic switch-off in regadenoson Rb-PET myocardial perfusion imaging: assessment of clinical utility.

Saad J, Ahmed A, Han Y, El Nihum L, Alahdab F, Nabi F J Nucl Cardiol. 2023; 30(4):1484-1496.

PMID: 36607537 DOI: 10.1007/s12350-022-03158-3.

References

Cavalcante J, Barboza J, Ananthasubramaniam K . Regadenoson is a safe and well-tolerated pharmacological stress agent for myocardial perfusion imaging in post-heart transplant patients. J Nucl Cardiol. 2011; 18(4):628-33. DOI: 10.1007/s12350-011-9399-3. View

van Dijk R, Kuijpers D, Kaandorp T, van Dijkman P, Vliegenthart R, van der Harst P . Effects of caffeine intake prior to stress cardiac magnetic resonance perfusion imaging on regadenoson- versus adenosine-induced hyperemia as measured by T1 mapping. Int J Cardiovasc Imaging. 2017; 33(11):1753-1759. PMC: 5682854. DOI: 10.1007/s10554-017-1157-4. View

Gaemperli O, Schepis T, Koepfli P, Siegrist P, Fleischman S, Nguyen P . Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by positron emission tomography: a randomized, double-blind, placebo-controlled crossover trial. J Am Coll Cardiol. 2008; 51(3):328-9. DOI: 10.1016/j.jacc.2007.10.014. View

Doran J, Sajjad W, Schneider M, Gupta R, Mackin M, Schwartz R . Aminophylline and caffeine for reversal of adverse symptoms associated with regadenoson SPECT MPI. J Nucl Cardiol. 2016; 24(3):1062-1070. DOI: 10.1007/s12350-016-0452-0. View

Shryock J, Snowdy S, Baraldi P, Cacciari B, Spalluto G, Monopoli A . A2A-adenosine receptor reserve for coronary vasodilation. Circulation. 1998; 98(7):711-8. DOI: 10.1161/01.cir.98.7.711. View

Lim Y, Teo S, Poh K . ST-segment changes with exercise stress. Singapore Med J. 2016; 57(7):347-53. PMC: 4958709. DOI: 10.11622/smedj.2016116. View

Fukuda M, Suzuki Y, Hino H, Morimoto T, Ishii E . Activation of central adenosine A(2A) receptors lowers the seizure threshold of hyperthermia-induced seizure in childhood rats. Seizure. 2010; 20(2):156-9. DOI: 10.1016/j.seizure.2010.11.012. View

Gao Z, Li Z, Baker S, Lasley R, Meyer S, Elzein E . Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2A agonists. J Pharmacol Exp Ther. 2001; 298(1):209-18. View

Hirao M, Oku H, Goto W, Sugiyama T, Kobayashi T, Ikeda T . Effects of adenosine on optic nerve head circulation in rabbits. Exp Eye Res. 2004; 79(5):729-35. DOI: 10.1016/j.exer.2004.08.008. View

10.

Gordi T, Frohna P, Sun H, Wolff A, Belardinelli L, Lieu H . A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Clin Pharmacokinet. 2006; 45(12):1201-12. DOI: 10.2165/00003088-200645120-00005. View

11.

Thomas G, Tammelin B, Schiffman G, Marquez R, Rice D, Milikien D . Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial (RegCOPD trial). J Nucl Cardiol. 2008; 15(3):319-28. DOI: 10.1016/j.nuclcard.2008.02.013. View

12.

Posch M, Kay M, Harhash A, Huang J, Krupinski E, Abidov A . Daily Caffeine Consumption Is Associated with Decreased Incidence of Symptoms and Hemodynamic Changes During Pharmacologic Stress with Regadenoson. J Nucl Med Technol. 2019; 48(1):73-76. DOI: 10.2967/jnmt.118.225219. View

13.

Page 2nd R, Spurck P, Bainbridge J, Michalek J, Quaife R . Seizures associated with regadenoson: a case series. J Nucl Cardiol. 2011; 19(2):389-91. DOI: 10.1007/s12350-011-9461-1. View

14.

Lieu H, Shryock J, von Mering G, Gordi T, Blackburn B, Olmsted A . Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol. 2007; 14(4):514-20. DOI: 10.1016/j.nuclcard.2007.02.016. View

15.

Garner K, Pomeroy W, Arnold J . Exercise Stress Testing: Indications and Common Questions. Am Fam Physician. 2017; 96(5):293-299. View

16.

Kleppisch T, Nelson M . Adenosine activates ATP-sensitive potassium channels in arterial myocytes via A2 receptors and cAMP-dependent protein kinase. Proc Natl Acad Sci U S A. 1995; 92(26):12441-5. PMC: 40373. DOI: 10.1073/pnas.92.26.12441. View

17.

Prenner B, Bukofzer S, Behm S, Feaheny K, McNutt B . A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. J Nucl Cardiol. 2012; 19(4):681-92. PMC: 3395344. DOI: 10.1007/s12350-012-9547-4. View

18.

Doukky R, Rangel M, Wassouf M, Dick R, Alqaid A, Morales Demori R . The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation. J Nucl Cardiol. 2012; 20(2):205-13. DOI: 10.1007/s12350-012-9654-2. View

19.

Henzlova M, Duvall W, Einstein A, Travin M, Verberne H . ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers. J Nucl Cardiol. 2016; 23(3):606-39. DOI: 10.1007/s12350-015-0387-x. View

20.

Iskandrian A, Bateman T, Belardinelli L, Blackburn B, Cerqueira M, Hendel R . Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol. 2007; 14(5):645-58. DOI: 10.1016/j.nuclcard.2007.06.114. View